Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome

References

• Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44.
   PubMedGoogle Scholar
• Kumar L, Ramavath D, Kataria B, for AIIMS Myeloma Group, et al. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome. Indian J Med Res. 2019;149(6):730–739.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Martinez-Lopez J, Grande C, et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the spanish registry for transplantation in multiple myeloma. Br J Haematol. 2000;109(1):138–147.
   PubMed Web of Science ®Google Scholar
• Bashir Q, Thall PF, Milton DR, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May;6(5):e266–e275.
   PubMed Web of Science ®Google Scholar
• Rodriguez TE, Hari P, Stiff PJ, et al. Busulfan, melphalan, and bortezomib versus High-Dose melphalan as a conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2016;22(8):1391–1396.
   PubMed Web of Science ®Google Scholar
• Barta SK, Jain R, Mazumder A, et al. Pharmacokinetics-directed intravenous busulfan combined with high-dose melphalan and bortezomib as a conditioning regimen for patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2017;17(10):650–657.
   PubMed Web of Science ®Google Scholar
• Blanes M, González JD, Lahuerta JJ, et al. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2015;56(2):415–419.
   PubMed Web of Science ®Google Scholar
• Hagen P, D'Souza A, Hari P, et al. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. Leuk Lymphoma. 2020;61(14):3484–3492.
   PubMed Web of Science ®Google Scholar
• Martino M, Tripepi G, Messina G, et al. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Bone Marrow Transplant. 2016;51(9):1197–1203.
   PubMed Web of Science ®Google Scholar
• Kumar L, Iqbal N, Mookerjee A, et al. Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med. 2014;3(4):939–946.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Herzig RH, Graham-Pole J, et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol. 1983;1(6):359–367.
   PubMed Web of Science ®Google Scholar
• Garderet L, Beohou E, Caillot D, et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Haematologica. 2016;101(11):1390–1397.
   PubMed Web of Science ®Google Scholar
• Ghilardi G, Pabst T, Jeker B, Swiss Blood Stem Cell Transplantation Registry, et al. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplant. 2019;54(7):1029–1037.
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822–829.
   PubMed Web of Science ®Google Scholar
• Auner HW, Iacobelli S, Sbianchi G, et al. Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT chronic malignancies working party. Haematologica. 2018;103(3):514–521.
   PubMed Web of Science ®Google Scholar
• Srour SA, Milton DR, Bashir Q, et al. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021;106(12):3211–3214.
   PubMed Web of Science ®Google Scholar
• Kumar K, Subash C. Comparison of 140mg/m2 vs 200mg/m2 dose of melphalan in myeloma autograft - a single Centre experience from chennai, India. Blood. 2020;136(Supplement 1):34–35.
   Google Scholar
• Katragadda L, McCullough LM, Dai Y, et al. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience. Clin Transplant. 2016;30(8):894–900.
   PubMed Web of Science ®Google Scholar
• Kumar L, Gundu N, Kancharia H, AIIMS Myeloma Group, et al. AIIMS myeloma group. Multiple Myeloma-Effect of induction therapy on transplant outcomes. Clin Lymphoma Myeloma Leuk. 2021; Feb21(2):80–90.e5.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919.
   PubMed Web of Science ®Google Scholar
• Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) – MDCalc Accessed on 19th June2022.
   Google Scholar
• Prakash VS, Malik PS, Sahoo RK, et al. Multiple myeloma: risk adapted use of plerixafor for stem cell mobilization prior to autologous stem cell transplantation is effective and cost efficient. Clin Lymphoma Myeloma Leuk. 2022;22(1):44–51. Aug 2: s 2152-2650(21)00313-X.
   PubMed Web of Science ®Google Scholar
• Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European group for blood and marrow transplant. Br J Haematol. 1998;102(5):1115–1123.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Oliver-Caldes A, Soler-Perromat JC, Lozano E, et al. Long-Term responders after autologous stem cell transplantation in multiple myeloma. Front Oncol. 2022;12:936993.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Chandramohan J, Kumar L. AML transformation after autologous stem cell transplant for multiple myeloma BMJ. Case Reports. 2015;2015(May29 1):bcr2015210024–bcr2015210024.
   PubMedGoogle Scholar
• Narwal A, Ramteke P, Kumar L, et al. Renal cell carcinoma concomitant with multiple myeloma. J Pathol Transl Med. 2022;56(2):111–112.
   PubMed Web of Science ®Google Scholar
• Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20(3):402–408.e1.
   PubMed Web of Science ®Google Scholar